Clinical Laserthermia Systems AB (FRA:LS60) Cyclically Adjusted Revenue per Share: €0.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LS60 Clinical Laserthermia Systems AB FRA:LS60
41 GF Score
Price €0.12
GF Value €0.16
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Clinical Laserthermia Systems AB Cyclically Adjusted Revenue per Share?

Clinical Laserthermia Systems AB FRA:LS60 +2.04% 41 Cyclically Adjusted Revenue per Share is €0.18 as of Jun. 2026. GuruFocus rates FRA:LS60 with a GF Score™ of 41/100 and a GF Value™ of €0.16 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Clinical Laserthermia Systems AB's adjusted revenue per share for the three months ended in Jun. 2026 was €0.022. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.18 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Clinical Laserthermia Systems AB's average Cyclically Adjusted Revenue Growth Rate was -4.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Clinical Laserthermia Systems AB was 26.30% per year. The lowest was 0.60% per year. And the median was 14.50% per year.

As of today (2026-09-03), Clinical Laserthermia Systems AB's current stock price is €0.1198. Clinical Laserthermia Systems AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.18. Clinical Laserthermia Systems AB's Cyclically Adjusted PS Ratio of today is 0.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Clinical Laserthermia Systems AB was 522.35. The lowest was 0.82. And the median was 96.01.


Clinical Laserthermia Systems AB  (FRA:LS60) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Clinical Laserthermia Systems AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.1198/0.18
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Clinical Laserthermia Systems AB was 522.35. The lowest was 0.82. And the median was 96.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Clinical Laserthermia Systems AB Cyclically Adjusted Revenue per Share Related Terms


Clinical Laserthermia Systems AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Clinical Laserthermia Systems AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinical Laserthermia Systems AB Cyclically Adjusted Revenue per Share Chart

Clinical Laserthermia Systems AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.24 0.12 0.18 0.20

Clinical Laserthermia Systems AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.20 0.19 0.18

FRA:LS60 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Clinical Laserthermia Systems AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinical Laserthermia Systems AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Clinical Laserthermia Systems AB's Cyclically Adjusted PS Ratio falls into.


FRA:LS60
41GF Score
Clinical Laserthermia Systems AB FRA:LS60
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinical Laserthermia Systems AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Clinical Laserthermia Systems AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.022/134.6100*134.6100
=0.022

Current CPI (Jun. 2026) = 134.6100.

Clinical Laserthermia Systems AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.042 103.279 0.055
201712 0.052 103.793 0.067
201803 0.066 103.962 0.085
201806 0.115 104.875 0.148
201809 0.017 105.679 0.022
201812 0.054 105.912 0.069
201903 0.013 105.886 0.017
201906 0.035 106.742 0.044
201909 0.122 107.214 0.153
201912 0.015 107.766 0.019
202003 0.027 106.563 0.034
202006 0.032 107.498 0.040
202009 0.087 107.635 0.109
202012 -0.004 108.296 -0.005
202103 0.098 108.360 0.122
202106 0.000 108.928 0.000
202109 0.001 110.338 0.001
202112 0.100 112.486 0.120
202203 0.064 114.825 0.075
202206 0.033 118.384 0.038
202209 0.041 122.296 0.045
202212 0.186 126.365 0.198
202303 0.020 127.042 0.021
202306 0.041 129.407 0.043
202309 0.032 130.224 0.033
202312 0.059 131.912 0.060
202403 0.042 132.205 0.043
202406 0.035 132.716 0.035
202409 0.036 132.304 0.037
202412 0.027 132.987 0.027
202503 0.019 132.825 0.019
202506 0.033 133.699 0.033
202509 0.010 133.480 0.010
202512 0.002 133.390 0.002
202603 0.004 133.560 0.004
202606 0.022 134.610 0.022

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.18 mean?
Clinical Laserthermia Systems AB (FRA:LS60) has a Cyclically Adjusted Revenue per Share of €0.18 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Clinical Laserthermia Systems AB and its competitors.
Is Clinical Laserthermia Systems AB's Cyclically Adjusted Revenue per Share too high?
Clinical Laserthermia Systems AB's current Cyclically Adjusted Revenue per Share is €0.18. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Clinical Laserthermia Systems AB's Cyclically Adjusted Revenue per Share of €0.18 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Clinical Laserthermia Systems AB and its competitors. Clinical Laserthermia Systems AB's current Cyclically Adjusted Revenue per Share is €0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Possible Value Trap. The stock's GF Value™ is €0.16, compared to a current price of €0.12 — trading 25.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.18. Clinical Laserthermia Systems AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current Cyclically Adjusted Revenue per Share is €0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?

Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued. The current stock price of €0.12 is trading 25.1% below its estimated GF Value™ of €0.16. GuruFocus considers Clinical Laserthermia Systems AB to be Possible Value Trap.

Key valuation signals for FRA:LS60:

  • Cyclically Adjusted Revenue per Share: €0.18
  • GF Value™: €0.16 vs. price of €0.12 (25.1% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clinical Laserthermia Systems AB Business Description

Other Exchanges CLS B:Sweden
Address Scheelevagen 2, Medicon village, Lund, SWE, 223 81
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
41GF Score

Get the complete analysis for FRA:LS60

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.16
GF Value